Company: IXHL
Filing Date: 2025-04-28
Form Type: 424B3
Source: 0001213900-25-036065
Chunk: 5

Company: Incannex Healthcare Inc.
Filing Date: 2025-04-28
Form: 424B3
Chunk 5
---
or implied by, these assumptions and estimates. You should read the information contained in, or incorporated by reference into, this
prospectus completely and with the understanding that future results may be materially different from and worse than what we expect. See
the information included under the heading “Special Note Regarding Forward-Looking Statements.”

In this prospectus, references
to “Incannex,” “Incannex Healthcare,” the “Company,” “we,” “us,” and “our”
refer to Incannex Healthcare Inc. and its subsidiaries. The phrase “this prospectus” refers to this prospectus and any applicable
prospectus, unless the context requires otherwise.

We use our trademarks in
this prospectus as well as trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience,
certain trademarks and tradenames referred to in this prospectus appear without the ® and TM symbols, but those references
are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the
applicable owner will not assert its rights, to these trademarks and tradenames.

<div align='center'>ii

PROSPECTUS SUMMARY</div>

The following is a summary of what we believe to be the most important aspects of our business and the offering of our securities under this prospectus. We urge you to read this entire prospectus, including the more detailed consolidated financial statements, notes to the consolidated financial statements and other information incorporated by reference from our other filings with the SEC. Investing in our securities involves risks. Therefore, carefully consider the risk factors set forth in this prospectus and in our most recent annual and quarterly filings with the SEC, as well as other information in this prospectus and the documents incorporated by reference herein.

About Incannex Healthcare Inc.

We are a clinical-stage biopharmaceutical
development company dedicated to developing combination medicines that target the underlying biological pathways associated with chronic
conditions, including obstructive sleep apnea (“OSA”), rheumatoid arthritis and generalized anxiety disorder. We are advancing
novel oral fix-dosed treatments and therapeutic regimens based on evidence-based innovation. Our lead Phase 2/3 and Phase 2 clinical programs
include IHL-42X for the treatment of OSA; IHL-675A for the treatment of inflammatory conditions, including rheumatoid arthritis, and PSX-001,
our oral synthetic psilocybin treatment, in combination with psychotherapy